Cost-effectiveness analysis of interferon Beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis. Caloyeras JP, Zhang B, Wang C, Eriksson M, Fredrikson S, Beckmann K, Knappertz V, Pohl C, Hartung H-P, Shah D, et al. Clin Ther. 2012 May; 34(5):1132-44. Epub 2012 Apr 27. PMID: 22541587. Abstract CommentRecommendBookmarkWatch